Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide

Japanese Journal of Clinical Oncology

Volumn 37, Issue 12, 2007, Pages 897-906

  Nagane, Motoo ^a   Kobayashi, Keiichi ^a   Ohnishi, Akiko ^b   Shimizu, Saki ^a,c   Shiokawa, Yoshiaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c Brainpier Minamiohta ^*  (Japan)

Author keywords

Glioblastoma; O6 methylguanine DNA methyltransferase; Recurrence; Temozolomide; Western blot

Indexed keywords

CORTICOSTEROID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; NITROSOUREA DERIVATIVE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LEUKOCYTE; LIVER DYSFUNCTION; LUNG TOXICITY; LYMPHOCYTE; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT CANCER; SCHOOL CHILD; SIDE EFFECT; SKIN ALLERGY; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WESTERN BLOTTING; CENTRAL NERVOUS SYSTEM TUMOR; CHEMISTRY; CHILD; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; PREDICTION AND FORECASTING; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 38749146312     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym132     Document Type: Article

References (49)

1. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnos malignant glioma in adults: A systematic review. Radiother Oncol 2002;64:259-73.
2. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
3. Hickman JA, Stevens MF, Gibson NW, Langdon SP, Fizames C, Lavelle F, et al. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res 1985;45:3008-13.
4. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5946-52.
5. Tsang LL, Farmer PB, Gescher A, Slack JA. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 1990;26:429-36.
6. Yung WK. Temozolomide in malignant gliomas. Semin Oncol 2000;27:27-34.
7. van den, Bent Mi, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-8.
8. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
10. Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ, et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinoncs and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 1995;38:1493-504.
11. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 1987;36:457-62.
12. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002;20:2388-99.
13. 6-alkguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995;51:167-223.
14. 6-methylguanine DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors. Jpn J Clin Oncol 1992;22:143-9.
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
16. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
17. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 2007;25:1470-5.
18. 6'-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
19. Paz Mf, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguine-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004;10:4933-8.
20. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006;95:1155-60.
21. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 2005;11:5167-74.
22. Stupp R, Hegi ME. Methylguanine methyltransferase testing in glioblastoma: When and how? J Clin Oncol 2007;25:1459-60.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nalt Cancer Inst 2000;92:205-16.
24. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
25. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJS. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56;5079-86.
26. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistani glioma cells to temozolomide. J Neurosurg 2003;99:1047-52.
27. Gerson SL. MGMT: Its role in cancer actiology and, cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
28. 6-methylguanine- deoxyribonucleic acid methyltransferase messenger ribonucleic acid for therapy of malignant gliomas. Neurosurgery 1997;41:434-40. Discussion in 1997;41:40-1.
29. Teixeira MM, Garcia I, Portela I, Cemuda M, Oliveira C, Albano J, et al. Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: Experience from a Portuguese institution. Int J Clin Pharmacol Res 2002;22:19-22.
30. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study. Oncology 2002;63:38-41.
31. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-66.
32. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83:598-93.
33. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomido-induced mitotic catastrophe and cellular senescence. Cancer Res 2005;65:4861-9.
34. Hirose Y, Katayama M, Berger MS, Pieper RO. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 2004; 100: 1060-5.
35. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001;61:5843-9.
36. 6-methylguanine-DNA methyltranspherase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 2003; 103:67-72.
37. 6 -alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 2006;5:2531-9.
38. Kreklau EL, Limp-Foster M, Liu N, Xu Y, Kelley MR, Erickson LC. A novel fluorometric oligonucleotide assay to measure 0(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing mqthylpurine DNA glycosylase. Nucleic Acids Res 2001;29:2558-66.
39. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
40. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-85.
41. 6-methylguanine-DNA methylftransferase messenger RNA in paraffin-embedded human astrocytic tumor tissues by nested in situ RT-PCR is useful in predicting chemotherapy-resistance of tumors. Int J Oncol 2003;22:543-9.
42. 6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin Cancer Res 1997;3:2459-63.
43. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-11.
44. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-5.
45. 6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 2005;23:7646-53.
46. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005;23:7178-87.
47. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phaic II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 2004;22:1598-604.
48. Newlands, ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003,89:248-51.
49. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.